Advancements in Immune Tolerance

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2007 Nov 3

PMID 17976856

Citations 10

Authors

Ping-Ying Pan

Junko Ozao

Zuping Zhou

Shu-Hsia Chen

Affiliations

Soon will be listed here.

Abstract

In recent years, considerable attention has been given to immune tolerance and its potential clinical applications for the treatment of cancers and autoimmune diseases, and the prevention of allo-graft rejection and graft-versus-host diseases. Advances in our understanding of the underlying mechanisms of establishment and maintenance of immune tolerance in various experimental settings and animal models, and in our ability to manipulate the development of various immune tolerogenic cells in vitro and in vivo, have generated significant momentum for the field of cell-based tolerogenic therapy. This review briefly summarizes the major tolerogenic cell populations and their mechanisms of action, while focusing mainly on potential exploitation of their tolerogenic mechanisms for clinical applications.

Citing Articles

Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4.

Xu Y, Kang K, Coakley B, Eisenstein S, Parveen A, Mai S EMBO J. 2025; .

PMID: 39948411 DOI: 10.1038/s44318-024-00330-y.

LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets.

Xiang Z, Yin X, Wei L, Peng M, Zhu Q, Lu X Biomolecules. 2024; 14(2).

PMID: 38397424 PMC: 10887124. DOI: 10.3390/biom14020187.

Developing Phytocompounds from Medicinal Plants as Immunomodulators.

Wen C, Chen H, Yang N Adv Bot Res. 2020; 62:197-272.

PMID: 32300254 PMC: 7150268. DOI: 10.1016/B978-0-12-394591-4.00004-0.

HisgAtlas 1.0: a human immunosuppression gene database.

Liu Y, He M, Wang D, Diao L, Liu J, Tang L Database (Oxford). 2019; 2017.

PMID: 31725860 PMC: 7243927. DOI: 10.1093/database/bax094.

The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.

Zhang J, Chen H, Ma G, Zhou Z, Raulet D, Rivera A Leukemia. 2019; 33(8):2078-2089.

PMID: 30737483 PMC: 6687551. DOI: 10.1038/s41375-019-0394-z.

References

Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone J, Herold K . Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006; 116(5):1371-81. PMC: 1440705. DOI: 10.1172/JCI27191. View

Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C . IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110(9):3192-201. PMC: 2200901. DOI: 10.1182/blood-2007-06-094615. View

Hammond K, Poulton L, Palmisano L, Silveira P, Godfrey D, Baxter A . alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 1998; 187(7):1047-56. PMC: 2212199. DOI: 10.1084/jem.187.7.1047. View

Mars L, Laloux V, Goude K, Desbois S, Saoudi A, Van Kaer L . Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol. 2002; 168(12):6007-11. DOI: 10.4049/jimmunol.168.12.6007. View

Takahashi T, KUNIYASU Y, Toda M, Sakaguchi N, Itoh M, Iwata M . Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1999; 10(12):1969-80. DOI: 10.1093/intimm/10.12.1969. View

You S, Leforban B, Garcia C, Bach J, Bluestone J, Chatenoud L . Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007; 104(15):6335-40. PMC: 1851030. DOI: 10.1073/pnas.0701171104. View

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

Shevach E . From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006; 25(2):195-201. DOI: 10.1016/j.immuni.2006.08.003. View

Mahnke K, Qian Y, Knop J, Enk A . Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood. 2003; 101(12):4862-9. DOI: 10.1182/blood-2002-10-3229. View

10.

Weber W, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, Schumacher R . Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2005; 36(2):296-304. DOI: 10.1002/eji.200535616. View

11.

Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P . Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005; 65(12):5020-6. DOI: 10.1158/0008-5472.CAN-04-4043. View

12.

Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K . Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest. 2004; 114(2):270-9. PMC: 449749. DOI: 10.1172/JCI21275. View

13.

Mellor A, Baban B, Chandler P, Manlapat A, Kahler D, Munn D . Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol. 2005; 175(9):5601-5. DOI: 10.4049/jimmunol.175.9.5601. View

14.

Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N . Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones.... J Immunol. 1994; 152(6):3119-27. View

15.

von Mehren M . Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2007; 6 Suppl 1:S30-4. DOI: 10.3816/ccc.2006.s.005. View

16.

Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk A . Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood. 1999; 93(5):1634-42. View

17.

Van Ginderachter J, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G . Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006; 211(6-8):487-501. DOI: 10.1016/j.imbio.2006.06.002. View

18.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

19.

Munn D, Mellor A . The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006; 213:146-58. DOI: 10.1111/j.1600-065X.2006.00444.x. View

20.

Hanash A, Levy R . Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood. 2004; 105(4):1828-36. DOI: 10.1182/blood-2004-08-3213. View